Haleon Toekomstige groei

Future criteriumcontroles 1/6

Haleon zal naar verwachting groeien in winst en omzet met respectievelijk 10.6% en 3.6% per jaar. De winst per aandeel zal naar verwachting groeien met 13% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.5% zijn.

Belangrijke informatie

10.6%

Groei van de winst

13.0%

Groei van de winst per aandeel

Personal Products winstgroei	25.3%
Inkomstengroei	3.6%
Toekomstig rendement op eigen vermogen	9.5%
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NYSE:HLN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	11,998	1,813	1,883	N/A	13
12/31/2025	11,484	1,664	1,730	N/A	16
12/31/2024	11,224	1,487	1,451	N/A	15
9/30/2024	11,240	1,208	N/A	N/A	N/A
6/30/2024	11,258	1,088	2,455	2,193	N/A
3/31/2024	11,235	1,083	N/A	N/A	N/A
12/31/2023	11,302	1,049	2,010	2,100	N/A
9/30/2023	11,314	1,250	N/A	N/A	N/A
6/30/2023	11,408	1,230	1,796	2,132	N/A
3/31/2023	11,217	1,106	N/A	N/A	N/A
12/31/2022	10,858	1,060	1,771	2,063	N/A
9/30/2022	10,560	1,390	N/A	N/A	N/A
6/30/2022	10,158	1,416	1,604	1,802	N/A
3/31/2022	9,866	1,500	N/A	N/A	N/A
12/31/2021	9,545	1,390	1,195	1,356	N/A
12/31/2020	9,892	1,145	2,013	1,407	N/A
12/31/2019	8,480	655	663	786	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei HLN ( 10.6% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van HLN ( 10.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).

Hoge groeiwinsten: De winst van HLN zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van HLN ( 3.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van HLN ( 3.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen HLN zal naar verwachting over 3 jaar laag zijn ( 9.5 %).

Haleon Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Recent updates

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven